Kestra Private Wealth Services LLC Has $15.97 Million Position in Johnson & Johnson (NYSE:JNJ)

Kestra Private Wealth Services LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 5.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 110,408 shares of the company’s stock after buying an additional 6,187 shares during the period. Kestra Private Wealth Services LLC’s holdings in Johnson & Johnson were worth $15,967,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of JNJ. AMF Tjanstepension AB grew its stake in shares of Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at approximately $209,000. Wealth Group Ltd. bought a new stake in shares of Johnson & Johnson during the third quarter worth $213,000. Wedge Capital Management L L P NC grew its position in Johnson & Johnson by 2.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock worth $655,000 after acquiring an additional 86 shares during the last quarter. Finally, Creative Planning boosted its stake in shares of Johnson & Johnson by 4.3% during the third quarter. Creative Planning now owns 988,403 shares of the company’s stock valued at $160,181,000 after purchasing an additional 41,082 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $155.23 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $373.73 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The stock’s fifty day simple moving average is $147.48 and its two-hundred day simple moving average is $156.01.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analyst Ratings Changes

Several research firms recently commented on JNJ. Morgan Stanley cut their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Citigroup reduced their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Buying and Selling

In other news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.